Eli Lilly and Company

Eli Lilly and Company Shs Unsponsored Canadian Depository Receipt Hedged's next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, Eli Lilly and Company Shs Unsponsored Canadian Depository Receipt Hedged maintains a current ratio of 1.35, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 162.07, indicating elevated leverage, while an interest coverage ratio of 198.95 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Eli Lilly and Company Shs Unsponsored Canadian Depository Receipt Hedged posted a return on equity (ROE) of 102.44, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 34.73 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 21.97, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 36.53, useful for judging operating efficiency across full business cycles. The company generates approximately 2.30M in revenue per employee across its workforce of 49,250.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.95 indicates how many times Eli Lilly and Company Shs Unsponsored Canadian Depository Receipt Hedged sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Eli Lilly and Company Shs Unsponsored Canadian Depository Receipt Hedged recorded 9.77B in income tax expense. That works out to an effective tax rate of 20.49, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 47.68B, leaving 37.91B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

These figures are as of the close on October 22, 2026. The 50-day moving average sits at 12.57, while the 200-day moving average is 11.53.

These figures cover the twelve months ended June 30, 2026. EBITDA reached 50.71B, while operating income came in at 56.21B.

As of June 30, 2026, Eli Lilly and Company Shs Unsponsored Canadian Depository Receipt Hedged holds 12.70B in cash and equivalents against 77.93B in total debt, resulting in a net debt position of 65.22B. Total book value stands at 48.08B, with working capital of 24.03B providing operational flexibility.

Eli Lilly and Company Shs Unsponsored Canadian Depository Receipt Hedged produced 39.86B in operating cash flow over the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Eli Lilly and Company Shs Unsponsored Canadian Depository Receipt Hedged posted a gross margin of 83.40, reflecting its pricing power and cost economics. The operating margin of 49.72 and net profit margin of 33.53 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. The dividend payout ratio of 21.66 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth.